公开(公告)号：US20160185826A1

公开(公告)日：2016-06-30

申请号：US15015249

申请日：2016-02-04

Applicant: Medigen Biotechnology Corp.

Inventor： Young-Sun LIN ,  Jinyi CHENG ,  Ya-Lin CHIANG ,  Ming-Cheng CHEN ,  Kuei-Tai A. LAI ,  Chih Ya YANG

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/29 ,  A61K39/125 ,  A61K39/15 ,  C12N7/00 ,  A61K39/145

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/40 ,  C12N7/00 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12334 ,  C12N2720/12371 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10171 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/16022 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/16071 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/28171 ,  C12N2770/32322 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32371 ,  C12N2770/32422 ,  C12N2770/32423 ,  C12N2770/32434 ,  C12N2770/32471 ,  Y02A50/467

Abstract: The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

Abstract translation: 本发明涉及包含这种二聚融合蛋白的二聚融合蛋白和病毒样颗粒。 这些二聚融合蛋白包含携带在两个病毒结构蛋白或其片段之间的抗原或抗原性片段，其具有或不具有接头，相对于传统的单体平台，使抗原或抗原片段和病毒结构蛋白之间的空间位阻最小化 或其片段。 这种新颖的设计提供了多价疫苗和增强的免疫原性。 本发明还涉及编码这种二聚融合蛋白的核酸和包含这种核酸的宿主细胞。 本发明还涉及包含本发明的二聚融合蛋白和/或病毒样颗粒的药物组合物，以及使用这种组合物的预防或治疗方法。

公开(公告)号：US09872895B2

公开(公告)日：2018-01-23

申请号：US13825349

申请日：2011-09-20

Applicant: Andrew T. Gewirtz ,  Benyue Zhang

Inventor： Andrew T. Gewirtz ,  Benyue Zhang

IPC: A61K38/16 ,  A61K39/02 ,  A61K38/21 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K39/02 ,  A61K38/164 ,  A61K38/21 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/58 ,  C12N2720/12371 ,  Y02A50/388 ,  Y02A50/467 ,  A61K2300/00

Abstract: The disclosure relates to antiviral therapeutic methods and related compositions. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection by administering a pharmaceutical composition comprising a TLR5 ligand, such as a flagellin, to a subject in need thereof.

公开(公告)号：US20150165009A1

公开(公告)日：2015-06-18

申请号：US13825349

申请日：2011-09-20

Applicant: Andrew T. Gewirtz ,  Benyue Zhang

Inventor： Andrew T. Gewirtz ,  Benyue Zhang

IPC: A61K39/02 ,  A61K45/06

CPC classification number: A61K39/02 ,  A61K38/164 ,  A61K38/21 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/58 ,  C12N2720/12371 ,  Y02A50/388 ,  Y02A50/467 ,  A61K2300/00

Abstract: The disclosure relates to antiviral therapeutic methods and related compositions. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection by administering a pharmaceutical composition comprising a TLR5 ligand, such as a flagellin, to a subject in need thereof.

Abstract translation: 本公开涉及抗病毒治疗方法和相关组合物。 在某些实施方案中，本公开涉及通过向有需要的受试者施用包含TLR5配体（例如鞭毛蛋白）的药物组合物来治疗或预防病毒感染的方法。